HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.107.047381v1 49/5/804    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheng, Z. Articles by Gambhir, S. S. Search for Related Content PubMed PubMed Citation Articles by Cheng, Z. Articles by Gambhir, S. S.

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific ¹⁸F-Labeled Protein Scaffold Molecules

¹ Molecular Imaging Program at Stanford, Departments of Radiology and Bioengineering, Bio-X Program, Stanford University, Stanford, California; and ² Global Research, General Electric Company, Niskayuna, New York

Correspondence: For correspondence or reprints contact: Sanjiv Sam Gambhir, Molecular Imaging Program at Stanford, Departments of Radiology and Bioengineering, Bio-X Program, Clark Center, E-150, 318 Campus Dr., Stanford University, Stanford, CA 94305. E-mail: sgambhir{at}stanford.edu

Human epidermal growth factor receptor type 2 (HER2) is a well-established tumor biomarker that is overexpressed in a wide variety of cancers and that serves as a molecular target for therapeutic intervention. HER2 also serves as a prognostic indicator of patient survival and as a predictive marker of the response to antineoplastic therapy. The development of ¹⁸F-labeled biomolecules for PET imaging of HER2 (HER2 PET) is very important because it may provide a powerful tool for the early detection of HER2-positive tumor recurrence and for the monitoring of HER2-based tumor treatment. Methods: In this study, anti-HER2 monomeric and dimeric protein scaffold molecules [Z_HER2:477 and (Z_HER2:477)₂, respectively] were radiofluorinated at a reasonable radiochemical yield (13%–18%) by use of site-specific oxime chemistry. The resulting radiofluorinated protein scaffold molecules were then evaluated as potential molecular probes for small-animal HER2 PET by use of a SKOV3 tumor–bearing mouse model. Results: The 4-¹⁸F-fluorobenzaldehyde conjugated aminooxy-protein scaffolds [¹⁸F-N-(4-fluorobenzylidene)oxime (FBO)-Z_HER2:477 and ¹⁸F-FBO-(Z_HER2:477)₂] both displayed specific HER2-binding ability in vitro. Biodistribution and small-animal PET imaging studies further revealed that ¹⁸F-FBO-Z_HER2:477 showed rapid and high SKOV3 tumor accumulation and quick clearance from normal tissues, whereas ¹⁸F-FBO-(Z_HER2:477)₂ showed poor in vivo performance (low tumor uptake and tumor-to-normal tissue ratios). The specificity of ¹⁸F-FBO-Z_HER2:477 for SKOV3 tumors was confirmed by its lower uptake on pretreatment of tumor-bearing mice with the HER2-targeting agents Z_HER2 and trastuzumab. Moreover, small-animal PET imaging studies revealed that ¹⁸F-FBO-Z_HER2:477 produced higher-quality tumor imaging than ¹⁸F-FBO-(Z_HER2:477)₂. ¹⁸F-FBO-Z_HER2:477 could clearly identify HER2-positive tumors with good contrast. Conclusion: Overall, these data demonstrate that ¹⁸F-FBO-Z_HER2:477 is a promising PET probe for imaging HER2 expression in living mice. It has a high potential for translation to clinical applications. The radiofluorination method developed can also be used as a general strategy for the site-specific labeling of other proteins with ¹⁸F. The protein scaffold molecules used here are attractive for the further development of PET probes for other molecular targets.

Key Words: Affibody • HER2 • PET • imaging • ¹⁸F

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				G. Ren, R. Zhang, Z. Liu, J. M. Webster, Z. Miao, S. S. Gambhir, F. A. Syud, and Z. Cheng A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression J. Nucl. Med., September 1, 2009; 50(9): 1492 - 1499. [Abstract] [Full Text] [PDF]

				G. Kramer-Marek, D. O. Kiesewetter, and J. Capala Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules J. Nucl. Med., July 1, 2009; 50(7): 1131 - 1139. [Abstract] [Full Text] [PDF]

				A. Orlova, H. Wallberg, S. Stone-Elander, and V. Tolmachev On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model J. Nucl. Med., March 1, 2009; 50(3): 417 - 425. [Abstract] [Full Text] [PDF]

				R. E. Laing, M. A. Walter, D. O. Campbell, H. R. Herschman, N. Satyamurthy, M. E. Phelps, J. Czernin, O. N. Witte, and C. G. Radu Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography PNAS, February 24, 2009; 106(8): 2847 - 2852. [Abstract] [Full Text] [PDF]

				M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Ann. Onc., February 1, 2009; 20(2): 213 - 226. [Abstract] [Full Text] [PDF]